Canada’s federal and provincial government bureaucracies are taking more than two-and-a-half years on average to approve new prescription drugs, thereby depriving many Canadians of the latest in new medicines, finds a new report from the Fraser Institute, Canada’s leading public policy think-tank.
“On average, it takes Health Canada nearly 16 months to approve new drugs as safe and effective. After that, the provinces typically spend another 15 months or more deciding whether new medicines will be eligible for public reimbursement under provincial drug plans,” said Mark Rovere, Fraser Institute associate director of health policy studies and co-author of a report titled Access Delayed, Access Denied: Waiting for New Medicines in Canada.
Canada’s drug approval process involves two separate stages: First, Health Canada must certify a drug is safe and effective, then provincial governments decide if the drug will be reimbursed under their public drug programs. This combination of federal and provincial decision-making creates delays or, more often, deprives patients of access to new medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze